Advancing Heart Care: A New Chapter with the BrioVAD Study

Published date: |
Estimated read time: |
Authored by:
  • AdventHealth Research Institute
Topics:
Care

The AdventHealth Transplant team is proud to announce the launch of an important new clinical study evaluating BrioVAD, a next-generation heart device designed to transform treatment options for patients with advanced heart failure. This innovative technology represents a major step forward in the ongoing effort to improve patient outcomes and expand the possibilities of mechanical circulatory support.

Following the completion of Core Training for the INNOVATE 2254936 Vidic trial, AdventHealth officially became one of the select centers in the country to introduce BrioVAD. The team successfully completed its Site Initiation Visit (SIV) on August 11, shortly after the FDA granted clearance for the pivotal trial. With these key milestones achieved, the Transplant team is already preparing to enroll their first patient in the study—an exciting moment that marks the beginning of a new era in cardiovascular innovation at AdventHealth.

This accomplishment reflects the team’s unwavering commitment to advancing heart failure care through research, collaboration, and clinical excellence. By participating in this pivotal trial, AdventHealth continues to strengthen its role as a leader in cardiac innovation—delivering hope, healing, and cutting-edge care to patients facing some of the most complex heart conditions.

Recent News

News

Did you know? Women, Hormones, and Heart Risk

Heart disease is often thought of as a “man’s disease,” but it remains the leading cause of death for women in the United States. We asked Katie Love, MD, MSc, an investigator at the AdventHealth...

Read Article